Ranolazine-induced Elevation of Creatinine Kinase in the Absence of Statin Usage

Ranolazine received Food and Drug Administration (FDA) approval in 2006 for the treatment of chronic angina. Ranolazine has previously been linked to the development of statin-induced myopathy, because it also inhibits CYP3A4, which increases serum statin levels. In the absence of concomitant statin...

Descripción completa

Detalles Bibliográficos
Autores principales: Dein, Eric, Manno, Rebecca, Syed, Abrahim, Douglas, Homeyra, Geetha, Duvuru, Timlin, Homa
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Cureus 2018
Materias:
Internal Medicine
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6101463/
https://www.ncbi.nlm.nih.gov/pubmed/30131925
http://dx.doi.org/10.7759/cureus.2832
Descripción
Sumario:Ranolazine received Food and Drug Administration (FDA) approval in 2006 for the treatment of chronic angina. Ranolazine has previously been linked to the development of statin-induced myopathy, because it also inhibits CYP3A4, which increases serum statin levels. In the absence of concomitant statin therapy, elevated creatinine kinase (CK) and myalgias on ranolazine monotherapy has never been reported.

Ejemplares similares